Tuberous Sclerosis & mTOR Pathway
Tuberous sclerosis complex (TSC) is an autosomal dominant, multisystem disorder caused by loss-of-function pathogenic variants in either TSC1 (hamartin) or TSC2 (tuberin), both of which are negative regulators of the mechanistic target of rapamycin (mTOR) signaling pathway. The resulting constitutive activation of the mTOR pathway drives uncontrolled cell growth and proliferation, producing characteristic hamartomas in the brain, skin, kidneys, heart, and lungs. Neurologically, TSC is one of the most important genetic causes of epilepsy, with up to 85–90% of affected individuals developing seizures—most commonly infantile epileptic spasms or focal seizures—often beginning in the first year of life. TSC exemplifies the paradigm of precision medicine in epilepsy: the identification of mTOR pathway hyperactivation as the disease mechanism led directly to the FDA approval of the mTOR inhibitor everolimus for both TSC-associated subependymal giant cell astrocytomas (SEGAs) and drug-resistant focal seizures. Vigabatrin remains the first-line antiseizure medication for infantile spasms in TSC, with response rates of 65–95%.
Bottom Line
- Genetics: Autosomal dominant; TSC1 (chromosome 9q34) or TSC2 (chromosome 16p13.3) loss-of-function variants; ~65% are de novo; TSC2 variants typically cause more severe neurologic disease than TSC1
- mTOR pathway: TSC1-TSC2 complex inhibits Rheb (Ras homolog enriched in brain), preventing mTORC1 activation; loss of TSC1 or TSC2 → constitutive mTORC1 activation → increased cell growth, proliferation, and protein synthesis → hamartoma formation
- Neurologic manifestations: Cortical tubers (found in >80%), subependymal nodules (SENs), subependymal giant cell astrocytomas (SEGAs, 5–20%), white matter radial migration lines; epilepsy in 85–90%; intellectual disability in ~50%; autism spectrum disorder in ~50%
- Epilepsy: Most common neurologic feature; infantile spasms in ~40%; focal seizures in >60%; vigabatrin is first-line for infantile spasms in TSC; everolimus is FDA-approved for drug-resistant focal seizures
- Multisystem surveillance: Lifelong monitoring of brain (MRI), kidneys (angiomyolipomas, cysts), heart (rhabdomyomas), lungs (LAM in women), skin, and eyes is essential per consensus guidelines
Genetics
TSC1 and TSC2 Genes
TSC is caused by pathogenic variants in one of two tumor suppressor genes:
| Feature | TSC1 | TSC2 |
|---|---|---|
| Chromosome | 9q34 | 16p13.3 |
| Protein product | Hamartin | Tuberin |
| Proportion of TSC cases | ~20–30% | ~60–70% |
| De novo variants | ~65% of all TSC cases are de novo (new mutation not inherited from either parent) | Same; de novo variants are more common in TSC2 than TSC1 |
| Phenotype severity | Generally milder disease; later seizure onset; less intellectual disability | Generally more severe; earlier seizure onset; higher rate of intellectual disability and autism; larger and more numerous cortical tubers |
| No mutation identified (NMI) | ~10–15% of clinically diagnosed TSC patients have no identifiable variant on standard genetic testing; mosaicism, deep intronic variants, or large deletions may account for some of these cases | |
mTOR Signaling Pathway
The TSC1-TSC2 protein complex (hamartin-tuberin) functions as a GTPase-activating protein (GAP) for Rheb (Ras homolog enriched in brain). In the normal state:
- TSC1-TSC2 complex active → Converts Rheb-GTP to Rheb-GDP (inactive) → mTORC1 is suppressed → controlled cell growth and protein synthesis
- Loss of TSC1 or TSC2 → Rheb remains in active GTP-bound state → constitutive mTORC1 activation → increased protein synthesis (via S6K1 and 4E-BP1), cell growth, and proliferation
- Upstream regulators: PI3K/AKT pathway phosphorylates and inhibits the TSC complex; AMPK pathway activates the TSC complex in response to energy stress; loss of TSC function disconnects mTORC1 from these regulatory inputs
- Therapeutic target: mTOR inhibitors (everolimus, sirolimus) restore the downstream suppression of mTORC1, reducing cell growth and proliferation in TSC-associated tumors and, to some degree, suppressing seizure activity
TSC Diagnostic Criteria (2021 Updated Consensus)
- Definite TSC: Identification of a pathogenic TSC1 or TSC2 variant, OR two or more major clinical features, OR one major + two or more minor features
- Possible TSC: One major feature, OR one major + one minor feature, OR two or more minor features
- Major features: Hypomelanotic macules (≥3, each ≥5 mm), angiofibromas (≥3) or fibrous cephalic plaque, ungual fibromas (≥2), shagreen patch, retinal hamartomas, cortical tubers, subependymal nodules, SEGA, cardiac rhabdomyoma, lymphangioleiomyomatosis (LAM), renal angiomyolipomas (≥2)
- Minor features: Confetti skin lesions, dental enamel pits (>3), intraoral fibromas (≥2), retinal achromic patch, multiple renal cysts, nonrenal hamartomas, sclerotic bone lesions
Neurologic Manifestations
Structural Brain Lesions
| Lesion Type | Frequency | Imaging Characteristics | Clinical Significance |
|---|---|---|---|
| Cortical tubers | >80% | T2/FLAIR hyperintense, T1 hypointense cortical/subcortical lesions; may calcify with age; variable size and number | Primary epileptogenic foci; tuber burden correlates with epilepsy severity and cognitive outcomes; cystic tubers associated with more severe epilepsy |
| Subependymal nodules (SENs) | ~80–90% | Small, calcified nodules along the ventricular walls; T1 iso- to hyperintense; "candle dripping" appearance | Usually clinically silent; may grow and transform into SEGAs; baseline for surveillance |
| Subependymal giant cell astrocytomas (SEGAs) | ~5–20% | Growing, enhancing mass near the foramen of Monro; >1 cm; serial growth on MRI | Risk of obstructive hydrocephalus; treatment with everolimus (first-line for asymptomatic growing SEGAs) or surgical resection (symptomatic/hydrocephalus) |
| White matter radial migration lines | ~50–60% | Linear T2/FLAIR hyperintensities extending from ventricle to cortex | Represent abnormal neuronal migration; may contribute to connectivity disruption; do not require treatment |
Epilepsy in TSC
Epilepsy is the most common neurologic manifestation of TSC and the leading cause of morbidity:
- Prevalence: 85–90% of TSC patients develop seizures; two-thirds have seizure onset in the first year of life
- Seizure types: Infantile spasms (~40%), focal seizures (~60–70%), generalized tonic-clonic seizures; multiple seizure types may coexist
- Drug resistance: Approximately 60–70% of TSC patients with epilepsy develop drug-resistant seizures
- Epileptogenic foci: Cortical tubers are the primary epileptogenic substrate; the "dominant tuber" hypothesis suggests that a single tuber may generate most seizures, making targeted resection feasible
- Epilepsy surgery: Approximately 50–60% of carefully selected TSC patients achieve seizure freedom after resective surgery; presurgical evaluation with stereo-EEG or intracranial monitoring can identify the epileptogenic tuber(s)
Treatment of Epilepsy in TSC
Vigabatrin: First-Line for Infantile Spasms in TSC
Vigabatrin is uniquely effective for infantile spasms in TSC, with response rates substantially higher than in non-TSC etiologies:
- Mechanism: Irreversible inhibition of GABA transaminase, increasing synaptic GABA concentration; may also have direct effects on mTOR signaling
- Efficacy: 65–95% spasm cessation rate in TSC-associated infantile spasms (compared with ~35–50% in non-TSC etiologies)
- Dosing: 100–150 mg/kg/day in 2 divided doses; may be increased up to 200 mg/kg/day
- Retinal toxicity: Irreversible bilateral concentric visual field constriction occurs in 25–50% of patients with prolonged use; ophthalmologic monitoring is required; limit treatment duration when possible
- EPISTOP and PREVeNT trials: Preventive treatment with vigabatrin in TSC infants with epileptiform EEG abnormalities but no clinical seizures reduced the risk of developing clinical seizures and improved developmental outcomes; this evidence supports proactive EEG monitoring and early intervention
Everolimus: mTOR Inhibitor for Seizures
Everolimus is an mTOR inhibitor FDA-approved for two TSC indications: SEGA requiring intervention and drug-resistant focal-onset seizures:
| Indication | Trial | Key Results | Dosing and Monitoring |
|---|---|---|---|
| SEGA | EXIST-1 | 35% had ≥50% SEGA volume reduction vs. 0% placebo; durable responses over years; alternative to surgical resection for asymptomatic growing SEGAs | Target trough level 5–15 ng/mL; requires long-term treatment (SEGA regrows if discontinued) |
| Drug-resistant focal seizures | EXIST-3 | 40% responder rate (high-exposure) vs. 15% placebo; median 39.6% seizure frequency reduction; sustained benefit in open-label extension | Target trough level 5–15 ng/mL for seizures; FDA-approved for age ≥2 years |
- Side effects: Stomatitis (most common; manage with topical dexamethasone mouth rinse), upper respiratory infections, hyperlipidemia, hyperglycemia, immunosuppression
- Monitoring: Trough drug levels every 2 weeks until stable, then every 3–6 months; CBC, lipids, glucose, renal function; pneumocystis prophylaxis is NOT routinely required at standard doses
- Duration: Lifelong for SEGA (regrowth occurs with discontinuation); duration for seizure control is individualized
Antiseizure Medication Strategy in TSC
- Infantile spasms: Vigabatrin is first-line; if spasms persist, add hormonal therapy (ACTH or prednisolone); consider everolimus as adjunctive therapy
- Focal seizures: Standard focal epilepsy medications (oxcarbazepine, levetiracetam, lacosamide); add everolimus for drug-resistant focal seizures
- Epilepsy surgery: Consider early in drug-resistant cases; presurgical evaluation can identify a dominant epileptogenic tuber; approximately 50–60% achieve seizure freedom post-surgery
- Ketogenic diet: Effective adjunctive therapy in TSC-related epilepsy
- Preventive strategy (EPISTOP model): Serial EEGs in the first year of life; initiate vigabatrin at the first sign of epileptiform discharges, before clinical seizures develop
Multisystem Manifestations and Surveillance
| Organ System | Manifestation | Frequency | Surveillance | Treatment |
|---|---|---|---|---|
| Skin | Hypomelanotic macules, facial angiofibromas, shagreen patch, ungual fibromas | >90% | Skin examination annually; Wood lamp for subtle lesions | Topical sirolimus for facial angiofibromas; laser therapy |
| Kidney | Angiomyolipomas (AMLs), renal cysts, rarely renal cell carcinoma | ~80% (AMLs) | Renal MRI or ultrasound every 1–3 years; blood pressure annually | Everolimus for growing AMLs (≥3 cm); selective embolization for acute hemorrhage; avoid nephrectomy if possible |
| Heart | Cardiac rhabdomyomas (may cause arrhythmias, outflow obstruction) | ~50–70% (fetal/neonatal); regress spontaneously in most | Echocardiogram at diagnosis; then every 1–3 years in childhood; ECG for arrhythmia surveillance | Surgery for hemodynamically significant obstruction (rare); most regress by childhood |
| Lung | Lymphangioleiomyomatosis (LAM); multifocal micronodular pneumocyte hyperplasia | ~30–40% of adult women | Baseline chest HRCT at age 18 for women; then every 5–10 years if normal; lung function tests if symptomatic | Sirolimus for progressive LAM; avoid estrogen-containing contraceptives |
| Eyes | Retinal hamartomas, achromic patches | ~40–50% | Ophthalmologic examination at diagnosis, then annually in childhood | Usually asymptomatic; treat only if threatening vision |
| Brain | Cortical tubers, SENs, SEGAs; epilepsy, intellectual disability, autism, behavioral issues | >80% (brain lesions); 85–90% (epilepsy) | Brain MRI every 1–3 years until age 25; then less frequently if stable; EEG as clinically indicated; neuropsychological assessment | See epilepsy treatment above; everolimus for SEGAs; neurodevelopmental support |
Epilepsy Surgery in TSC
Epilepsy surgery is an important and underutilized treatment option for drug-resistant epilepsy in TSC. The presence of multiple cortical tubers does not preclude surgical candidacy, as careful presurgical evaluation can often identify a dominant epileptogenic tuber responsible for the majority of seizures:
| Aspect | Details |
|---|---|
| Candidate identification | Drug-resistant epilepsy despite ≥2 appropriate ASMs; focal seizure semiology or EEG suggesting a dominant focus; cortical tuber(s) concordant with seizure localization |
| Presurgical evaluation | Epilepsy protocol MRI with 3T; video-EEG monitoring; PET scan (tubers with highest FDG uptake or surrounding hypometabolism are more epileptogenic); MEG for spike source localization; stereo-EEG may be required for invasive monitoring |
| Surgical approaches | Tuberectomy (resection of a single dominant tuber); lobectomy; multilobar resection; hemispherectomy for severe unilateral disease |
| Outcomes | 50–60% achieve seizure freedom (Engel class I); concordant MRI, PET, and EEG findings predict better outcomes; patients with a single dominant tuber have the best surgical outcomes |
| Timing | Early surgical evaluation is recommended for drug-resistant cases; earlier surgery (before age 2–3 years) is associated with better developmental outcomes by reducing the burden of epileptic encephalopathy during critical brain development |
Alpha-[11C]methyl-L-tryptophan PET in TSC
- Alpha-[11C]methyl-L-tryptophan (AMT) PET is a specialized imaging technique that identifies epileptogenic tubers with higher sensitivity than FDG-PET in some series
- Epileptogenic tubers demonstrate increased AMT uptake, reflecting increased tryptophan metabolism in dysplastic tissue
- This technique can help distinguish epileptogenic from non-epileptogenic tubers when multiple tubers are present, guiding more targeted surgical resection
- Availability is limited to specialized centers, but it represents an important tool in the presurgical evaluation of TSC patients
Neurodevelopmental Outcomes
The neurodevelopmental profile of TSC is highly variable, ranging from normal cognition to severe intellectual disability:
- Intellectual disability: Present in approximately 50% of TSC patients; more common with TSC2 variants, higher tuber burden, and early-onset drug-resistant epilepsy
- Autism spectrum disorder (ASD): Occurs in approximately 40–50%; may be related to disrupted connectivity from cortical tubers and white matter abnormalities
- TSC-associated neuropsychiatric disorders (TAND): A comprehensive term encompassing behavioral (aggression, self-injury, anxiety), psychiatric (depression, ADHD), and cognitive difficulties; should be assessed systematically using the TAND checklist
- Predictors of better cognitive outcomes: TSC1 genotype, fewer cortical tubers, later seizure onset, rapid seizure control, absence of infantile spasms
Critical Surveillance and Management Points
- All infants with a new diagnosis of TSC should undergo serial EEGs in the first year of life (at least every 4–6 weeks) to detect epileptiform discharges before clinical seizures emerge—early intervention may improve outcomes
- Monitor for SEGA growth with serial brain MRI every 1–3 years until age 25; acute headache, nausea/vomiting, or visual changes may indicate obstructive hydrocephalus
- Renal AMLs require lifelong surveillance; hemorrhage from AMLs ≥4 cm or with aneurysms >5 mm is a medical emergency
- All women with TSC should be screened for LAM starting at age 18; pregnancy planning requires multidisciplinary coordination (potential LAM exacerbation, medication adjustments)
- TAND screening should be performed at key developmental milestones; early intervention services for autism, intellectual disability, and behavioral challenges
References
- Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 2021;123:50–66.
- Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008;372(9639):657–668.
- French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016;388(10056):2153–2163.
- Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol 2021;89(2):304–314.
- Bebin EM, Peters JM, Porter BE, et al. Early treatment with vigabatrin does not decrease focal seizures or improve cognition in tuberous sclerosis complex: the PREVeNT trial. Ann Neurol 2024;95(4):730–740.
- Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013;49(4):255–265.
- Curatolo P, Nabbout R, Lagae L, et al. Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol 2018;22(5):738–748.
- Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381(9861):125–132.
- Jozwiak S, Kotulska K, Domanska-Pakiela D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Epilepsia 2011;52(10):e187–e190.
- Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell 2017;168(6):960–976.
- de Vries PJ, Whittemore VH, Leclezio L, et al. Tuberous sclerosis complex: a roadmap for future research. Pediatr Neurol 2020;112:14–20.